.015 to .0154 seems to have found a lot of support. Sure would like to see someone smash the .0154 that NITE has out there. They are line up at .016, .0175 and .025 thereafter. Any positive news from Pfizer on their phase III Bapineuzumab trial could send this through the roof since there is no real good AD prospects put there besides this one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.